Cutaneous T cell lymphomas (CTCL) represent a heterogeneous group of T-cell malignancies that manifest primarily in the skin. By far the most common variant of CTCL is mycosis fungoides and its ...
PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...
For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those ...
A new study by researchers at Karolinska Institutet and Karolinska University Hospital shows that patients diagnosed with the rare skin cancers mycosis fungoides and Sézary syndrome face a ...
PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today ...
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life ...
CRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc ...
Support groups and foundations can be invaluable for patients with mycosis fungoides and their families and caregivers. One of the most well-recognized organizations specifically for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results